(49 days)
Not Found
No
The device description focuses on the mechanical and electrical components (RF energy, bipolar electrodes, irrigation port) and does not mention any software, algorithms, or data processing that would indicate the use of AI or ML. The performance studies are bench tests and non-clinical studies on tissue, not evaluations of algorithmic performance.
Yes
The device is intended for "coagulation of active bleeding lesions" in the gastrointestinal tract, which directly addresses a medical condition (bleeding) and aims to restore normal physiological function (hemostasis).
No
The device is described as a hemostasis probe intended for coagulation of active bleeding, which is a therapeutic function, not a diagnostic one. It is used to treat a condition (bleeding), not to identify or characterize it.
No
The device description clearly details a physical probe with electrodes, an irrigation port, and specific dimensions, indicating it is a hardware device, not software-only.
Based on the provided information, the Gyrus ACMI BiCOAG Hemostasis Probe is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Device Function: The BiCOAG Hemostasis Probe is a surgical accessory used during an endoscopic procedure to directly treat bleeding lesions within the gastrointestinal tract using RF energy. It does not analyze or test samples taken from the body.
- Intended Use: The intended use clearly states it's for "coagulation of active bleeding lesions... during endoscopic procedures." This is a therapeutic intervention, not a diagnostic test.
- Device Description: The description focuses on its physical characteristics, how it delivers RF energy and irrigation fluid, and its use in conjunction with a generator and endoscope – all indicative of a surgical tool.
Therefore, the BiCOAG Hemostasis Probe is a therapeutic medical device used for hemostasis, not an IVD.
N/A
Intended Use / Indications for Use
The Gyrus ACMI BiCOAG Hemostasis Probe is intended for coagulation of active bleeding lesions in the upper or lower gastrointestinal tract during endoscopic procedures.
Product codes
KNS
Device Description
The BiCOAG Hemostasis Probe is a single use disposable high frequency RF accessory to be used in conjunction with a generator with bipolar frequency energy rated up to 500Vp-p. The BiCOAG Hemostasis Probe is intended to be used for coagulation of active bleeding lesions in the upper or lower gastrointestinal tract. It contains a central irrigation port. The probe is to be available in 10 Fr and 7 Fr (3.3mm and 2.3mm respectively) outer diameter configurations to allow its use through a minimum 3.7mm and 2.8mm endoscope working channel, respectively. The device is intended to be passed through the working channel of an endoscope to provide hemostasis throughout the gastrointestinal tract.
The BiCOAG Hemostasis Probe enables irrigating fluid (sterile water) to be delivered at the electrode tip. This fluid enables the clearing of blood and other substances that often impede vision and coagulation of the surgical site.
The probe is bipolar with electrodes that spiral down the tip in a uniform manner. These electrodes carry desiccating RF current to a site where bleeding is occurring and allows for coagulation at the target site. The hole at the end of the probe allows for irrigating water to clean the surgical site as required when used in conjunction with a bipolar generator and endoscope. The system thus provides endoscopic control and hemostasis of upper and lower GI bleeding by the application of bipolar energy.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
upper or lower gastrointestinal tract
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Design verification testing was carried out on the bench to ensure the performance and reliability of the proposed device all with passing results. Testing such as physical dimensions, flow rates, pull testing, leak testing, performance, electrical, packaging, shelf life, sterilization, and Biocompatibility were all carried out and met acceptance criteria. In addition, a non-clinical bench study was carried out by a trained user on porcine tissue to evaluate the coagulation of the proposed probe against the predicate, and a few other market competitors. All specifications of the BiCOAG Hemostasis Probe that required verification and/or validation to ensure the proposed device is substantially equivalent to the predicate BiCOAG Hemostasis Probe have successfully achieved the acceptance criteria and raised no new issues of safety or effectiveness.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.4300 Endoscopic electrosurgical unit and accessories.
(a)
Identification. An endoscopic electrosurgical unit and accessories is a device used to perform electrosurgical procedures through an endoscope. This generic type of device includes the electrosurgical generator, patient plate, electric biopsy forceps, electrode, flexible snare, electrosurgical alarm system, electrosurgical power supply unit, electrical clamp, self-opening rigid snare, flexible suction coagulator electrode, patient return wristlet, contact jelly, adaptor to the cord for transurethral surgical instruments, the electric cord for transurethral surgical instruments, and the transurethral desiccator.(b)
Classification. Class II (performance standards).
0
Gyrus ACMI, Inc. 136 Turnpike Road Southborough, MA 01772 BiCOAG Hemostasis Probe
510(K) SUMMARY
General Information
Manufacturer:
DEC 1 4 2012
大12331
rf
Gyrus ACMI 6845 Wedgewood Rd. Maple Grove, MN 55311 ERN: 3005975494
Gyrus ACMI 136 Turnpike Rd. Southborough, MA 01772-2104 ERN: 3003790304
Neil Kelly (508) 804-2690 neil.kelly@Olympus-OSTA.com
BiCOAG Hemostasis Probe
BiCOAG, BiCOAG Probe
October 26, 2012
Unit, Electrosurgical, Endoscopic (With or Without Accessories) Gastroenterology/Urology KNS 21 CFR 8876.4300 Class II
Trade Name:
Generic/Common Name:
Predicate Device
Gyrus ACMI BiCOAG Hemostasis Probe
Indications for Use
The Gyrus ACMI BiCOAG Hemostasis Probe is intended for coagulation of active bleeding lesions in the upper or lower gastrointestinal tract during endoscopic procedures.
Product Description
The BiCOAG Hemostasis Probe is a single use disposable high frequency RF accessory to be used in conjunction with a generator with bipolar frequency energy rated up to 500Vp-p. The BiCOAG Hemostasis Probe is intended to be used for coagulation of active bleeding lesions in the upper or lower gastrointestinal tract. It contains a central irrigation port. The probe is to be available in 10 Fr and 7 Fr (3.3mm and 2.3mm respectively) outer diameter configurations to allow its use through a minimum 3.7mm and 2.8mm endoscope working channel, respectively. The device is intended to be passed through the working channel of an endoscope to provide hemostasis throughout the gastrointestinal tract.
Page 10
P. 1/3 22
510(k) Submitter:
Contact Person:
Date Prepared:
Classification Name:
1
The BiCOAG Hemostasis Probe enables irrigating fluid (sterile water) to be delivered at the electrode tip. This fluid enables the clearing of blood and other substances that often impede vision and coagulation of the surgical site.
The probe is bipolar with electrodes that spiral down the tip in a uniform manner. These electrodes carry desiccating RF current to a site where bleeding is occurring and allows for coagulation at the target site. The hole at the end of the probe allows for irrigating water to clean the surgical site as required when used in conjunction with a bipolar generator and endoscope. The system thus provides endoscopic control and hemostasis of upper and lower GI bleeding by the application of bipolar energy.
| Change | Predicate Device K092571 (From) | Proposed Device (To) | Reason |
|---|---|---|---|
| Conductive Trace Material | Nickel-plated Palladium | Gold | Improves manufacturability. New material found to be biocompatible, and performed substantially equivalent to the predicate material. (Material) |
| Tip to Wire Electrical Joint | Tin-lead solder | Conductive epoxy | Improves manufacturability of electrical joint with gold trace material and proposed conductive epoxy is RoHS compliant. (Material, Component) |
| Wire to Power Cord Electrical Joint | Tin-lead solder | Tin-silver solder | Proposed solder is intended for electrical applications and is RoHS compliant. (Material) |
| 10Fr Tip Material | Machined alumina | Molded zirconia | Higher mechanical strength and improves manufacturability. Material already in use on the 7Fr predicate device. (Material) |
| Bifurcation Joint | Overmolded | Two-piece Assembly (potting cup and lid) | Improves reliability and resistance to leaks with improved flow. (Component) |
| Coaxial Plug | Manufactured | Purchased | Coaxial plug is an industry standard design and was readily available from an existing vendor. Removes steps from current manufacturing process. (Component) |
| Luer Adhesive Change | UV-cure adhesive | UV-cure adhesive with tint | Original adhesive has become obsolete by the vendor. New adhesive performs substantially equivalent to the original but changes color from blue to clear when cured which aids in assembly. (Material) |
| Tip to Body Stock Adhesive Change | Moisture-cure adhesive | Epoxy | Improved manufacturability and epoxy is RoHS compliant. (Material, Component) |
Proposed to Predicate Comparison
Page 11
P.2/3
23
2
These device modifications have been tested against the predicate device and are found to perform substantially equivalent. No new issues of safety or effectiveness are raised by these changes.
Performance Data. Technological features, and Substantial Equivalence
The Gyrus ACMI BiCOAG Hemostasis Probe, as described in this submission, is substantially equivalent to the predicates in intended use, principles of operation, performance, and fundamental scientific technology.
Design verification testing was carried out on the bench to ensure the performance and reliability of the proposed device all with passing results. Testing such as physical dimensions, flow rates, pull testing, leak testing, performance, electrical, packaging, shelf life, sterilization, and Biocompatibility were all carried out and met acceptance criteria. In addition, a non-clinical bench study was carried out by a trained user on porcine tissue to evaluate the coagulation of the proposed probe against the predicate, and a few other market competitors. All specifications of the BiCOAG Hemostasis Probe that required verification and/or validation to ensure the proposed device is substantially equivalent to the predicate BiCOAG Hemostasis Probe have successfully achieved the acceptance criteria and raised no new issues of safety or effectiveness.
Summary
The proposed Gyrus ACMI BiCOAG Hemostasis Probe, as described in this submission, raises no new issues of safety or effectiveness as compared to the predicate device and has been found substantially equivalent to the currently marketed predicate Gyrus ACMI BiCOAG Hemostasis Probe.
Page 12
p.3/3 2
3
Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized symbol resembling a bird or abstract human figure, with three curved lines representing the body and head. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the symbol. The logo is black and white.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
Olympus Surgical Technologies America % Mr. Neil Kelly Regulatory Affairs Specialist 136 Turnpike Road Southborough, Massachusetts 01772
December 14, 2012
Re: K123319
Trade/Device Name: Gyrus ACMI® BiCOAG Hemostatis Probe Regulation Number: 21 CFR 876.4300 Regulation Name: Endoscopic electrosurgical unit and accessories Regulatory Class: Class II Product Code: KNS Dated: November 21, 2012 Received: November 21, 2012
Dear Mr. Kelly:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
4
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely vours,
Peter D. Rumm -S
Mark N. Melkerson Acting Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Gyrus ACMJ、Inc. 136 Turnpike Road Southborough, MA 01772
Indications for Use Statement
510(k) Number: K123319
Device Name: Gyrus ACMI® BiCOAG Hemostasis Probe
Indications for Use:
The Gyrus ACMI BiCOAG Hemostasis Probe is intended for coagulation of active bleeding lesions in the upper or lower gastrointestinal tract during endoscopic procedures.
OR
Prescription Use:X
Over-the-Counter Use: ________________________________________________________________________________________________________________________________________________________
(Per 21 CFR 801.109)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Dwight Yen 2012.12.12 07:57:38 -05'00'
(Division Sign-Off)
Division of Surgical Devices
510(k) Number _K123319